Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.

CONCLUSIONS: Baseline tumor assessment before chemotherapy provides information that stratifies patients with complete resection into different prognostic groups. Integrating the data from different assessment methods might lead to improved definitions of prognostic groups. Further investigation to determine if earlier initiation of chemotherapy after debulking surgery could increase survival of patients with early tumor regrowth is warranted.
PMID: 30466805 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - November 19, 2018 Category: Cancer & Oncology Authors: Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A Tags: Gynecol Oncol Source Type: research